CASP1 and metabolic dysfunction-associated steatotic liver disease: A differential DNA methylation of pro- or antifibrogenic genes (i.e., transforming growth factor-β (TGFβ)1, platelet-derived growth factor (PDGF)α, or peroxisome proliferator-activated receptor (PPAR)α and PPARδ), genes encoding matrix molecules or remodeling factors, but also chemokines (CCR7 and CCL5) or factors related to the inflammasome (e.g., signal transducer and activator of transcription (STAT)1, and caspase 1 (CASP1)) has been observed in patients with NAFLD, and this was correlated to the fibrosis stage [80,81,82].